Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant vesicular stomatitis virus-expressing human interferon beta + sodium-iodide symporter
- Development stage
- Phase 2
- Lead developer
- Mayo Clinic
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
This is a genetically engineered, replication-competent oncolytic virus based on the Indiana strain of vesicular stomatitis virus (VSV). The construct expresses two transgenes: human interferon beta (hIFNβ) and the sodium-iodide symporter (NIS). The addition of hIFNβ enhances tumor selectivity by protecting normal cells from viral cytotoxicity while promoting direct tumor cell killing, apoptosis, inhibition of angiogenesis, and immunomodulation. The NIS gene enables noninvasive imaging of viral distribution using radioisotopes and may facilitate targeted radiotherapy. This agent is under clinical investigation primarily for advanced cancers including malignant solid tumors, non-small cell lung carcinoma, and acute myeloid leukemia[1][2][7].
- Other names
- recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genesoncolytic VSV expressing IFN-beta and sodium iodide symporter
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)NIS (Human sodium iodide symporter)
Beyond the preview
Go deeper on recombinant vesicular stomatitis virus-expressing human interferon beta + sodium-iodide symporter.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant vesicular stomatitis virus-expressing human interferon beta + sodium-iodide symporter.